Grit Biotechnology

This early-phase study is testing a new cell therapy called GT801 in 28 adults with relapsed or hard-to-treat B-cell blood cancers (like leukemia and lymphoma) or autoimmune hemolytic anemia (AIHA). The therapy uses a patient's own immune cells, modified to attack CD19-positive c…

This early-phase trial tests a new drug called GT801 in 22 people with moderate-to-severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…

This study tests an experimental therapy called GT201, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced solid tumors. About 18 adults will receive the treatment to see if it is safe and can shrink tumors. The goal is to control the disease, no…

This early study tests a new treatment called GT201, made from a patient's own tumor-fighting immune cells (TILs), combined with a PD-1 inhibitor drug. The goal is to see if this combination is safe and tolerable for 32 adults with advanced head and neck cancer that has returned …

This study tests a new treatment called GT101, which uses immune cells taken from a patient's own tumor to fight recurrent or metastatic cervical cancer. About 83 adults will receive either GT101 or a standard chemotherapy drug. The goal is to see if the cell therapy can delay ca…

This study tests a new therapy called GT307, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack advanced colorectal cancer. The trial enrolls 18 adults whose cancer has worsened after first-line chemotherapy. The main goals are to check safety and …

This early-stage trial is testing a new treatment called IB-T101 for people with advanced clear cell kidney cancer. The treatment uses a patient's own immune cells, called tumor-infiltrating lymphocytes, which are grown in a lab and then given back to the patient. The study will …

This early-phase study tests a personalized treatment called GT101 for adults with advanced solid tumors that have spread or come back. Doctors take immune cells from the patient's own tumor, grow them in a lab, and infuse them back after mild chemotherapy. The goal is to see if …

This study tests a new treatment called GT307, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight advanced solid tumors like ovarian cancer. The goal is to see if it is safe and can shrink tumors. About 18 adults aged 18-70 with relapsed or metastat…

This early-phase trial tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. The study will enroll 36 participants to check safety and see if the treatment can reduce symptoms. It's a first s…

This early-stage study tests an injection called GT719 in 30 people with moderate to severe autoimmune diseases like lupus that haven't responded to standard treatments. The main goal is to check safety and find the right dose, while also looking at whether it helps control disea…

This study tests a new treatment called GT307, made from a patient's own tumor-fighting immune cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the treatment is safe and to find the best dose.

This early-phase trial is testing an experimental immune cell therapy called GT719 in 34 adults with relapsed or refractory CD19-positive B-cell blood cancers (certain leukemias and lymphomas). The treatment uses specially engineered cells to target and destroy cancer cells. The …

This early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study wi…

This early-phase trial is testing an injection called GT719 in 10 adults with moderate to severe autoimmune diseases that haven't responded to other treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the therapy might h…

This early-phase trial is testing an experimental cell therapy called GT719 in 46 adults with relapsed or treatment-resistant B-cell lymphoma or leukemia that tests positive for CD19. The study aims to see if the treatment is safe and how well it works. Participants receive a sin…

This early-stage trial is testing a new cell therapy called GT719 in 30 adults with recurrent or hard-to-treat neurological autoimmune diseases. The goal is to see if it is safe and how long the cells last in the body. Researchers will also look for early signs that it might help…